Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O L Laskin

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
American Heart Journal|February 1, 1977
Dopamine and blood flowO L Laskin, J A Romankiewicz, M M Reidenberg
Clinical Pharmacology and Therapeutics|March 1, 1986
Pentamidine-induced hypoglycemia in patients with the acquired immune deficiency syndromeC M Stahl-Bayliss, C M Kalman, O L Laskin
Clinical Pharmacology and Therapeutics|November 1, 1983
Netilmicin and gentamicin multidose kinetics in normal subjectsO L Laskin, J A Longstreth, C R Smith, et al.
American Journal of Ophthalmology|April 15, 1986
Antiviral therapy for cytomegalovirus retinitis in AIDS with dihydroxy propoxymethyl guanineL R Rosecan, C M Stahl-Bayliss, C M Kalman, et al.
The Journal of Infectious Diseases|February 1, 1987
Use of ganciclovir to treat serious cytomegalovirus infections in patients with AIDSO L Laskin, C M Stahl-Bayliss, C M Kalman, et al.
The New England Journal of Medicine|July 9, 1981
Acyclovir prophylaxis of herpes-simplex-virus infectionsR Saral, W H Burns, O L Laskin, et al.
The American Journal of Medicine|July 20, 1982
Acyclovir concentrations and tolerance during repetitive administration for 18 daysO L Laskin, R Saral, W H Burns, et al.
Journal of Clinical Pharmacology|July 1, 1993
Pharmacodynamics and dose-response relationship of famotidine: a double-blind randomized placebo-controlled trialO L Laskin, P M Patterson, S Shingo, et al.
Ophthalmology|November 1, 1986
Antiviral therapy with ganciclovir for cytomegalovirus retinitis and bilateral exudative retinal detachments in an immunocompromised childL R Rosecan, O L Laskin, C M Kalman, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1982
Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humansO L Laskin, J A Longstreth, R Saral, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
American Heart Journal|February 1, 1977
Dopamine and blood flowO L Laskin, J A Romankiewicz, M M Reidenberg
Clinical Pharmacology and Therapeutics|March 1, 1986
Pentamidine-induced hypoglycemia in patients with the acquired immune deficiency syndromeC M Stahl-Bayliss, C M Kalman, O L Laskin
Clinical Pharmacology and Therapeutics|November 1, 1983
Netilmicin and gentamicin multidose kinetics in normal subjectsO L Laskin, J A Longstreth, C R Smith, et al.
American Journal of Ophthalmology|April 15, 1986
Antiviral therapy for cytomegalovirus retinitis in AIDS with dihydroxy propoxymethyl guanineL R Rosecan, C M Stahl-Bayliss, C M Kalman, et al.
The Journal of Infectious Diseases|February 1, 1987
Use of ganciclovir to treat serious cytomegalovirus infections in patients with AIDSO L Laskin, C M Stahl-Bayliss, C M Kalman, et al.
The New England Journal of Medicine|July 9, 1981
Acyclovir prophylaxis of herpes-simplex-virus infectionsR Saral, W H Burns, O L Laskin, et al.
The American Journal of Medicine|July 20, 1982
Acyclovir concentrations and tolerance during repetitive administration for 18 daysO L Laskin, R Saral, W H Burns, et al.
Journal of Clinical Pharmacology|July 1, 1993
Pharmacodynamics and dose-response relationship of famotidine: a double-blind randomized placebo-controlled trialO L Laskin, P M Patterson, S Shingo, et al.
Ophthalmology|November 1, 1986
Antiviral therapy with ganciclovir for cytomegalovirus retinitis and bilateral exudative retinal detachments in an immunocompromised childL R Rosecan, O L Laskin, C M Kalman, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1982
Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humansO L Laskin, J A Longstreth, R Saral, et al.
Pageof 5